+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dyskinesia - Pipeline Review, H1 2020

  • ID: 5017418
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 249 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Cerevance Inc
  • GW Pharmaceuticals Plc
  • Med-Life Discoveries LP
  • Neurolixis Inc
  • Sage Therapeutics Inc
  • MORE
Dyskinesia - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H1 2020, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 17, 8, 26 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Cerevance Inc
  • GW Pharmaceuticals Plc
  • Med-Life Discoveries LP
  • Neurolixis Inc
  • Sage Therapeutics Inc
  • MORE
  • Introduction
  • Dyskinesia - Overview
  • Dyskinesia - Therapeutics Development
  • Dyskinesia - Therapeutics Assessment
  • Dyskinesia - Companies Involved in Therapeutics Development
  • Dyskinesia - Drug Profiles
  • Dyskinesia - Dormant Projects
  • Dyskinesia - Discontinued Products
  • Dyskinesia - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Dyskinesia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Dyskinesia - Pipeline by Addex Therapeutics Ltd, H1 2020
  • Dyskinesia - Pipeline by Amarantus Bioscience Holdings Inc, H1 2020
  • Dyskinesia - Pipeline by Astraea Therapeutics LLC, H1 2020
  • Dyskinesia - Pipeline by Bod Australia Ltd, H1 2020
  • Dyskinesia - Pipeline by Cadent Therapeutics Inc, H1 2020
  • Dyskinesia - Pipeline by Cannabis Science Inc, H1 2020
  • Dyskinesia - Pipeline by Cavion LLC, H1 2020
  • Dyskinesia - Pipeline by Cerevance Inc, H1 2020
  • Dyskinesia - Pipeline by Cerevel Therapeutics LLC, H1 2020
  • Dyskinesia - Pipeline by Clevexel Pharma SAS, H1 2020
  • Dyskinesia - Pipeline by Contera Pharma ApS, H1 2020
  • Dyskinesia - Pipeline by DanPET AB, H1 2020
  • Dyskinesia - Pipeline by EpiVax Inc, H1 2020
  • Dyskinesia - Dormant Projects, H1 2020
  • Dyskinesia - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Dyskinesia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3
  • Addex Therapeutics Ltd
  • Amarantus Bioscience Holdings Inc
  • Astraea Therapeutics LLC
  • Bod Australia Ltd
  • Cadent Therapeutics Inc
  • Cannabis Science Inc
  • Cavion LLC
  • Cerevance Inc
  • Cerevel Therapeutics LLC
  • Clevexel Pharma SAS
  • Contera Pharma ApS
  • DanPET AB
  • EpiVax Inc
  • GW Pharmaceuticals Plc
  • H. Lundbeck AS
  • Hua Medicine Shanghai Ltd
  • Ipsen SA
  • IRLAB Therapeutics AB
  • Junaxo Inc
  • Med-Life Discoveries LP
  • Medytox Inc
  • Melior Pharmaceuticals II LLC
  • Merz Pharma GmbH & Co KgaA
  • MitoDys Therapeutics Ltd
  • Motac Neuroscience Ltd
  • NeurAxon Pharma Inc
  • Neurim Pharmaceuticals Ltd
  • Neurocea Pharmaceuticals
  • Neurocrine Biosciences Inc
  • Neurolixis Inc
  • Newron Pharmaceuticals SpA
  • Nissan Chemical Corp
  • OB Pharmaceuticals
  • Peptron Inc
  • PolyCore Therapeutics LLC
  • Praxis Precision Medicines Australia Pty Ltd
  • Prilenia Therapeutics Development Ltd
  • Revance Therapeutics Inc
  • Sage Therapeutics Inc
  • SalubRx Therapeutics Inc
  • Sinopia Biosciences Inc
  • SOM Biotech SL
  • Sosei Heptares
  • Teva Pharmaceutical Industries Ltd
  • Trevi Therapeutics Inc
  • Ultragenyx Pharmaceutical Inc
  • VistaGen Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll